U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07344948) titled 'Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia' on Nov. 14, 2025.
Brief Summary: This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
Study Start Date: Oct. 03, 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Schizophrenia Diagnosis
Intervention:
DRUG: NTX-253
Oral Capsule
DRUG: Placebo
Oral capsule
Recruitment Status: RECRUITING
Sponsor: Neurosterix
Published by HT Digital Content Services w...